Bioasis Technologies Inc. (BTI)の価格はいくらですか

Bioasis Technologies Inc. (BTI)の価格は$0.00366968です

Bioasis Technologies Inc. (BTI)の時価総額は何ですか

Bioasis Technologies Inc. (BTI)の時価総額は$291.42Kです

Bioasis Technologies Inc.（BTI）PER（株価収益率）

Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.

年	P/E比率	変化
提供された日付のデータは十分ではありません。

年

P/E比率

変化

提供された日付のデータは十分ではありません。

企業	P/E比率	P/E比率の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	28.05	-	US
Argenx SE ARGX.US	31.14	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	19.30	-	BE

企業

P/E比率

P/E比率の差

国